Bristol Myers Squibb Company
NEWS
Bayer, Bristol-Myers Squibb and Ono Pharmaceutical Co. have teamed up to study the most common type of metastatic colorectal cancer (mCRC).
In all three cancer types, data showed prolonged and consistent improvements in progression-free survival (PFS) that is similar to that seen with checkpoint inhibitor monotherapy.
As fireworks illuminate the night skies across the United States this weekend in celebration of Independence Day, BioSpace takes a look at some of the highlights of the pharma industry from the first half of 2019 and earlier that provides millions of patients with the independence of health.
According to a BioSpace poll, over half (56%) of respondents are not happy with their current life sciences position. Are you one of the 56%? You deserve to be happy! Start working towards your happiness and check out job opportunities at these top companies!
The month of July is a slow one for the U.S. Food and Drug Administration (FDA), at least in terms of scheduled approval dates. Here’s a look at the three PDUFA dates the agency has on its calendar for the month.
Exiting the last week of June and heading into July, a number of companies announced results from ongoing clinical trials. Here’s a look.
Draper, based in Cambridge, Massachusetts, signed a tissue model development deal with Bristol-Myers Squibb. The companies will collaborate on developing a unique liver tissue model to screen drugs for toxicity.
“Bristol-Myers Squibb is committed to working with regulatory authorities around the world on the proposed combination with Celgene,” the company stated. “The company is focused on realizing the promise of the transaction, and is continuing to work to complete the transaction on a timely basis.”
The facility has acted as one of Bristol-Myers Squibb’s primary launch facilities for new drugs. After the deal is closed, Catalent will continue to manufacture Bristol-Myers Squibb’s current product portfolio at that location.
JOBS
IN THE PRESS